ASKA Pharmaceutical Holdings Co.,Ltd. (TYO:4886)
Japan · Delayed Price · Currency is JPY 2,403.00
-30.00 (-1.23%)
Feb 13, 2026, 3:30 PM JST
TYO:4886 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 68,699 | 64,139 | 62,843 | 60,461 | 56,607 | 55,181 | |
Revenue Growth (YoY) | 7.43% | 2.06% | 3.94% | 6.81% | 2.58% | 5.02% |
Cost of Revenue | 35,495 | 32,803 | 32,178 | 31,876 | 30,255 | 29,798 |
Gross Profit | 33,204 | 31,336 | 30,665 | 28,585 | 26,352 | 25,383 |
Selling, General & Admin | 21,424 | 18,972 | 19,436 | 19,249 | 17,958 | 21,773 |
Research & Development | 7,031 | 7,031 | 4,728 | 4,227 | 3,598 | - |
Operating Expenses | 28,455 | 26,003 | 24,164 | 23,476 | 21,556 | 21,773 |
Operating Income | 4,749 | 5,333 | 6,501 | 5,109 | 4,796 | 3,610 |
Interest Expense | -178 | -51 | -40 | -50 | -56 | -59 |
Interest & Investment Income | 376 | 292 | 334 | 338 | 258 | 237 |
Earnings From Equity Investments | -159 | -53 | -41 | - | - | -453 |
Currency Exchange Gain (Loss) | -183 | -123 | -51 | -43 | - | - |
Other Non Operating Income (Expenses) | 17 | -184 | -169 | -70 | -75 | -243 |
EBT Excluding Unusual Items | 4,622 | 5,214 | 6,534 | 5,284 | 4,923 | 3,092 |
Gain (Loss) on Sale of Investments | 127 | 127 | 3,340 | 124 | -1,151 | 491 |
Gain (Loss) on Sale of Assets | -10 | -106 | -13 | -52 | 9,382 | -8 |
Asset Writedown | -300 | -300 | - | - | -5,953 | - |
Other Unusual Items | 1,257 | 1,257 | - | - | -1,038 | - |
Pretax Income | 5,696 | 6,192 | 9,861 | 5,356 | 6,163 | 3,575 |
Income Tax Expense | 665 | 1,091 | 2,316 | 1,118 | 1,873 | 862 |
Earnings From Continuing Operations | 5,031 | 5,101 | 7,545 | 4,238 | 4,290 | 2,713 |
Minority Interest in Earnings | -124 | - | - | - | - | - |
Net Income | 4,907 | 5,101 | 7,545 | 4,238 | 4,290 | 2,713 |
Net Income to Common | 4,907 | 5,101 | 7,545 | 4,238 | 4,290 | 2,713 |
Net Income Growth | -5.36% | -32.39% | 78.03% | -1.21% | 58.13% | 318.03% |
Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 28 | 28 |
Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 28 | 28 |
Shares Change (YoY) | 0.11% | 0.12% | 0.26% | -0.46% | 0.06% | 0.23% |
EPS (Basic) | 172.94 | 179.95 | 266.49 | 150.08 | 151.22 | 95.69 |
EPS (Diluted) | 172.94 | 179.95 | 266.49 | 150.08 | 151.22 | 95.69 |
EPS Growth | -5.48% | -32.47% | 77.57% | -0.75% | 58.03% | 317.09% |
Free Cash Flow | - | -475 | 166 | 2,890 | 2,263 | 5,437 |
Free Cash Flow Per Share | - | -16.76 | 5.86 | 102.34 | 79.77 | 191.76 |
Dividend Per Share | 57.000 | 55.000 | 40.000 | 16.000 | 15.000 | - |
Dividend Growth | 26.67% | 37.50% | 150.00% | 6.67% | - | - |
Gross Margin | - | 48.86% | 48.80% | 47.28% | 46.55% | 46.00% |
Operating Margin | 6.91% | 8.31% | 10.35% | 8.45% | 8.47% | 6.54% |
Profit Margin | 7.14% | 7.95% | 12.01% | 7.01% | 7.58% | 4.92% |
Free Cash Flow Margin | - | -0.74% | 0.26% | 4.78% | 4.00% | 9.85% |
EBITDA | 6,685 | 7,580 | 9,163 | 8,236 | 7,681 | 6,915 |
EBITDA Margin | - | 11.82% | 14.58% | 13.62% | 13.57% | 12.53% |
D&A For EBITDA | 1,936 | 2,247 | 2,662 | 3,127 | 2,885 | 3,305 |
EBIT | 4,749 | 5,333 | 6,501 | 5,109 | 4,796 | 3,610 |
EBIT Margin | - | 8.31% | 10.35% | 8.45% | 8.47% | 6.54% |
Effective Tax Rate | - | 17.62% | 23.49% | 20.87% | 30.39% | 24.11% |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.